SecBot SecBot
8-K ·Filed Nov 13, 2026

CRIS

CURIS INC
NEUTRAL
Impact 4/10
Horizonweeks Processed3d 11h ago SEC0001104659-26-127041
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Watch for initial TakeAim CLL data in December 2026, which could be a catalyst for the stock. The company's cash runway only extends into Q1 2027, so additional financing will likely be needed in 2027 absent a partnership or milestone payment.

DirectionNeutral
Confidencehigh
Horizonweeks

emavusertib

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2 (registrational-intent in PCNSL)
Time to market
Uncertain; the registrational PCNSL study is still enrolling with full enrollment targeted within 12-18 months from March 2026. If data are positive and an NDA follows, potential approval would be at least 2-3 years out, assuming sufficient capital to complete the trials.
Next catalyst
None dated

What to watchThe next major catalyst is a topline data readout from the registrational TakeAim Lymphoma study in PCNSL, which management targeted to fully enroll within 12-18 months from March 2026 (so late 2027 at the earliest). No specific readout date has been announced. In the near term, watch for the shareholder vote on the proposed reverse stock split, which the company needs to maintain Nasdaq listing, and for any further financing rounds given the cash burn (Q3 2026 net loss of $8.12M).

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Curis reported Q3 2026 net loss of $8.1M ($1.94 per share), narrower than the consensus estimate of a $2.01 loss per share. The company has no revenue following the 2025 sale of Erivedge royalties, and cash runway extended into Q1 2027 via an October 2026 private placement. Clinical progress continues in the TakeAim CLL and TakeAim Lymphoma studies, with initial CLL data expected December 2026.

Key Financial Metrics

EPS
−$1.94
est −$2.01 · +3.5%
Revenue
$0.00
est $0.00
Rating
beat

Key Facts

  • Q3 2026 net loss of $8.1 million, or $1.94 per share, vs. $7.7 million ($9.86 per share) in Q3 2025
  • No revenue reported for Q3 2026 due to sale of Erivedge royalties in Q4 2025
  • Cash and cash equivalents $5.0 million as of September 30, 2026
  • October 2026 private placement added net proceeds of approximately $7.5 million, extending cash runway into Q1 2027
  • 12 patients enrolled in TakeAim CLL study; initial data expected December 2026
  • TakeAim Lymphoma study in PCNSL continues as a registrational trial with FDA and EMA guidance for accelerated approval
  • Completed a public offering in August 2026 and a private placement in October 2026

Financial Impact

Net loss of $8.1 million for Q3 2026; cash runway extended to Q1 2027 with $5.0M cash plus $7.5M from October private placement

cash runwaynet lossdilution

Risk Factors

  • Cash runway only into Q1 2027; substantial additional capital needed to fund operations beyond that
  • No revenue stream; fully dependent on clinical trial success and financing
  • High dilution risk given multiple recent offerings (August 2026 public offering, October 2026 private placement)
  • Clinical trial risk for emavusertib in CLL and PCNSL; initial data due December 2026

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-127041
Document: tm2629651d1_8k.htm0001104659-26-127041
Document: 0001104659-26-127041-index-headers.html0001104659-26-127041
Document: 0001104659-26-127041-index.html0001104659-26-127041
Document: 0001104659-26-127041.txt0001104659-26-127041
8-K Data (Synthetic)0001104659-26-127041

Track record

18 reports on CRIS

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +82.45% at T+60 after the May 22, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.4200 Now $0.4400 +4.76% settles Nov 17
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.6000 Now $0.4400 −26.67% settles Nov 17
  3. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.5010 Now $0.4400 −12.18% settles Nov 17
  4. Nov 13, 20263d ago S-3 Bearish 7/10 Entry $0.6000 Now $0.4400 +26.67% settles Nov 17
  5. Nov 13, 20263d ago 8-K Neutral 4/10 Viewing Entry $0.4450 Now $0.4400 −1.12% settles Nov 17
  6. Nov 12, 20264d ago Press Release Bearish 6/10 Entry $0.4450 to $0.4358 Now $0.4400 +1.12% ▲ +2.07% +0.16% vs SPY
  7. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $0.6530 to $0.5915 Now $0.4400 −32.62% ▼ −9.42% −10.74% vs SPY
  8. Nov 6, 202610d ago 8-K Bearish 7/10 Entry $0.6976 to $0.6530 Now $0.4400 +36.93% ▲ +6.39% +6.03% vs SPY
  9. Nov 2, 202614d ago DEF 14A Neutral 4/10 Entry $0.6610 to $0.7139 Now $0.4400 −33.43% ▲ +8.00% +7.70% vs SPY
  10. Oct 19, 202628d ago 8-K Bearish 6/10 Entry $0.3996 to $0.3920 Now $0.4400 −10.11% ▲ +1.90% +2.43% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 6h 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026